Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Acronyms BELIEVE 1
- Sponsors Zynerba Pharmaceuticals
- 10 Apr 2018 According to a Zynerba Pharmaceuticals media release, this study has been initiated.
- 10 Apr 2018 Planned number of patients changed from 48 to 50, according to a Zynerba Pharmaceuticals media release.
- 10 Apr 2018 Status changed from planning to recruiting, according to a Zynerba Pharmaceuticals media release.